More recently, Hartman et al. found that once-weekly administration of tirzepatide for 26 weeks significantly reduced biomarkers of NASH and fibrosis (ALT, AST, keratin-18, and procollagen-C3) and increased adiponectin compared with placebo at a higher tirzepatide dose (15 mg) in patients with T2D [85]. Here, GPT is linked to metabolic dysfunction-associated steatohepatitis.